Zobrazeno 1 - 10
of 4 420
pro vyhledávání: '"Nintedanib"'
Publikováno v:
Journal of Medical Case Reports, Vol 18, Iss 1, Pp 1-5 (2024)
Abstract Background Nintedanib is a primary antifibrosing medication available for idiopathic pulmonary fibrosis, systemic sclerosis-interstitial lung disease, and progressive pulmonary fibrosis, with scattered report of drug-induced thrombocytopenia
Externí odkaz:
https://doaj.org/article/be806490f2a241eca771ade963d7902a
Autor:
Hironao Hozumi, Koichi Miyashita, Eiji Nakatani, Yusuke Inoue, Hideki Yasui, Yuzo Suzuki, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Naoki Inui, Takafumi Suda
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background and objective Pooled analyses of previous randomized controlled trials reported that antifibrotics improved survival in patients with idiopathic pulmonary fibrosis (IPF), but the results were only based on short-term outcome data
Externí odkaz:
https://doaj.org/article/7bdad9c4f3f34b3282e024e1cc282175
Publikováno v:
陆军军医大学学报, Vol 46, Iss 14, Pp 1695-1700 (2024)
Objective To investigate the key physical and chemical properties of nintedanib liposomes prepared by 4 different methods in order to screen out the best preparation method of nintedanib liposomes. Methods Firstly, nintedanib liposomes were prepared
Externí odkaz:
https://doaj.org/article/4fbbdea62a844519843a091928c909eb
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-9 (2024)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease (ILD) with a high mortality rate. The antifibrotic medications pirfenidone and nintedanib have been in use since 2014 for this disorder and are associa
Externí odkaz:
https://doaj.org/article/ac6a9a6c42f444e0b9bf33c9b73ee8ce
Autor:
Yusuke Ushio, Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Taichi Miyagi, Koichi Sugihara, Rina Mino, Mao Mizusaki, Kanako Chujo, Ryoko Kagawa, Hayamasa Yamaguchi, Norimitsu Kadowaki, Hiroaki Dobashi
Publikováno v:
BMC Rheumatology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Background In 2020, Nintedanib (NTB), a tyrosine kinase inhibitor, was the first drug approved worldwide for treating progressive fibrosing interstitial lung disease (PF-ILD). This study evaluated the efficacy and safety of NTB in Japanese p
Externí odkaz:
https://doaj.org/article/ab06a17021b64148a94417838e84ddcd
Autor:
B.C. Agema, M. Berrich, L. Seuren, S.D.T. Sassen, J.R. Miedema, B.C.P. Koch, M.S. Wijsenbeek, S.L.W. Koolen, R.H.J. Mathijssen, G.D.M. Veerman
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 179, Iss , Pp 117341- (2024)
Background: Nintedanib is used to treat both idiopathic and progressive pulmonary fibrosis (IPF/PPF). Evidence of both an exposure-response relationship and an exposure-toxicity relationship has been found, suggesting the potential value of therapeut
Externí odkaz:
https://doaj.org/article/ea5bbc70818248ff8532493c948a116b
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Sarcoidosis, an enigmatic disease with unknown etiology, is characterized by inflammation and the potential involvement of various organs, predominantly the lungs and intrathoracic lymph nodes. Non-caseating granulomas can resolve spontaneously in ap
Externí odkaz:
https://doaj.org/article/eb33c7faeb644bdba84da4d19f8fbc96
Autor:
Hari Baskar Balasubramanian, Sima Biswas, Maria Talmon, Filippo Patrucco, Piero Emilio Balbo, Luigia Grazia Fresu, Angshuman Bagchi
Publikováno v:
Borneo Journal of Pharmacy, Vol 7, Iss 3 (2024)
Idiopathic pulmonary fibrosis (IPF) is a progressive disease due to aggregation of fibroblasts on lung parenchyma. Nintedanib, an indolinone-derived tyrosine kinase inhibitor (TKi) has been approved for the treatment of IPF and it is a well-known inh
Externí odkaz:
https://doaj.org/article/e65e7e0165dd41e49210879376844d0f
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background The coronavirus disease 2019 (COVID-19) pandemic has had a significant impact on global health and economies, resulting in millions of infections and deaths. This retrospective cohort study aimed to investigate the effect of antif
Externí odkaz:
https://doaj.org/article/569af4dba306417b9769afbe60868144
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 12, Iss 1, Pp 8-16 (2024)
Aim: To demonstrate the possible protective efficacy of nintedanib, a tyrosine kinase inhibitor with demonstrated antifibrotic and antitumor activity, in a model of acute lung injury (ALI), a severe lung disease, through NLR family pyrin domain conta
Externí odkaz:
https://doaj.org/article/cde3955719d0427e9b6344cca0354466